📰 GeneralCNBCTuesday, October 20, 2026 at 12:50 PM UTC55m ago

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster GLP-1 obesity injection, Wegovy

Read full article at CNBC →

Originally published by CNBC. Summary and curation by DutyStation News.

← Back to News

Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysis

📰 Related Stories

TikTok employees said they knew about child safety issues, but execs failed to act

Adobe Lightroom mobile can now open closed eyes in photos with a simple tap

Jim Cramer's top 10 things to watch in the stock market Tuesday

Wii Sports is back on the Switch 2, and it rules

Final Fantasy dips back into the SNES golden era with Resonance

Inspired Capital closes $450M fourth fund as New York pushes back on Silicon Valley’s gravitational pull